FLT3 and acute myeloid leukemia: In contrast, chemotherapy (either Ara-C or Dox) followed by ABT-869 produces significant synergism on inhibition of proliferation and induction of apoptosis in MV4–11 and MOLM-14 cells, as well as primary patient AML cells with FLT3-ITD mutations [22].